Undervalued Biotech’s Product FDA-approved; Special Report by Leading Financial Web Site Penny Stock Detectives
In a recent Penny Stock Detectives article, editor Sasha Cekerevac argues that biotech companies live and die based on whether the drugs they’re developing can be approved by the U.S. Food and Drug Administration (FDA) and achieve sales success. Cekerevac notes that Protalix BioTherapeutics, Inc.’s main product “ELELYSO,” the first FDA-approved, plant-cell-based recombinant therapeutic protein, could translate into spectacular sales for the company.
New York, NY (PRWEB) July 04, 2012
In a recent Penny Stock Detectives article, editor Sasha Cekerevac argues that biotech companies live and die based on whether the drugs they’re developing can be approved by the U.S. Food and Drug Administration (FDA) and achieve sales success. Cekerevac notes that Protalix BioTherapeutics, Inc.’s main product “ELELYSO,” the first FDA-approved, plant-cell-based recombinant therapeutic protein, could translate into spectacular sales for the company.
“Protalix BioTherapeutics is one of only a few biotech companies attempting to revolutionize the development as well as the manufacturing of recombinant therapeutic proteins,” comments Cekerevac.
The FDA approved ELELYSO on May 1, 2012. Protalix is now partnering with Pfizer Inc. for the worldwide development and monetization of the drug. This is a great sign for the future, Cekerevac believes, as very few penny stocks are able to get such a product over the FDA’s hurdles. Cekerevac observes that biotech companies are notoriously “close” to approval, but remain below thresholds that the FDA requires.
“The actual process of manufacturing is quite unique when it comes to the various biotech companies,” comments Cekerevac. “Protalix uses plant cell cultures, namely carrot and tobacco, as opposed to the traditional method of mammalian or yeast-based systems for production. The process is very scalable. With the approval of ELELYSO, it shows that the system does indeed work.”
One of the main benefits is its lower cost, Cekerevac points out. Protalix reports that ELELYSO is approximately 25% cheaper to produce through plant cell cultures, as opposed to the traditional manufacturing systems. This should give Protalix an edge when competing against other biotech companies on cost, believes Cekerevac.
Following any news release, biotech companies will tend to bounce around. Cekerevac advises the investor to be cautious in this period, as the whipsaw effect can be difficult to gauge. It’s better to wait and see how the situation pans out. Biotech companies with a steady flow of investor interest also interest Cekerevac, who believes Protalix certainly fits that profile. This is a sign of confidence, he notes.
Biotech companies have several hurdles, including developing a new drug, gaining FDA approval, and generating sufficient sales to warrant the expenditures used, to overcome to get to that point. Cekerevac notes that Protalix has achieved and surpassed many hurdles, but it is yet to be seen how effectively this company can monetize its product and its new method of production.
“… biotech companies with a good idea are a dime a dozen,” concludes Cekerevac. “Biotech companies that have found an extremely profitable niche are far more rare and worth a look.”
To see the full article and to learn more about Penny Stock Detectives, visit http://www.pennystockdetectives.com.
The editors of Penny Stock Detectives believe low-priced stocks, when researched properly, present investors with great opportunities to accumulate wealth and to increase the value of their investment portfolios. You can learn more about Penny Stock Detectives at http://www.pennystockdetectives.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9662068.htm
